KR102513020B1 - 암 바이오마커로서 pd-ecgf - Google Patents

암 바이오마커로서 pd-ecgf Download PDF

Info

Publication number
KR102513020B1
KR102513020B1 KR1020177025613A KR20177025613A KR102513020B1 KR 102513020 B1 KR102513020 B1 KR 102513020B1 KR 1020177025613 A KR1020177025613 A KR 1020177025613A KR 20177025613 A KR20177025613 A KR 20177025613A KR 102513020 B1 KR102513020 B1 KR 102513020B1
Authority
KR
South Korea
Prior art keywords
ecgf
cancer
sample
level
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177025613A
Other languages
English (en)
Korean (ko)
Other versions
KR20170123638A (ko
Inventor
카사노바스 오리올 카사노바스
발레리오 가브리엘라 지메네즈
드 올자 마리아 오초아
페레즈 발렌티 나바로
니클라스 바사니
헬레나 베르다게르
Original Assignee
펀다시오 인스티튜트 드’인베스티가시오 바이오메티칼 드 벨리비티게 (아이디벨)
인스티튜트 카탈라 디’ 온코로기아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펀다시오 인스티튜트 드’인베스티가시오 바이오메티칼 드 벨리비티게 (아이디벨), 인스티튜트 카탈라 디’ 온코로기아 filed Critical 펀다시오 인스티튜트 드’인베스티가시오 바이오메티칼 드 벨리비티게 (아이디벨)
Publication of KR20170123638A publication Critical patent/KR20170123638A/ko
Application granted granted Critical
Publication of KR102513020B1 publication Critical patent/KR102513020B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G01N33/57415—
    • G01N33/57419—
    • G01N33/57438—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177025613A 2015-03-11 2016-03-10 암 바이오마커로서 pd-ecgf Active KR102513020B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382109.5 2015-03-11
EP15382109.5A EP3067698A1 (en) 2015-03-11 2015-03-11 Pd-ecgf as biomarker of cancer
PCT/EP2016/055143 WO2016142471A1 (en) 2015-03-11 2016-03-10 Pd-ecgf as biomarker of cancer

Publications (2)

Publication Number Publication Date
KR20170123638A KR20170123638A (ko) 2017-11-08
KR102513020B1 true KR102513020B1 (ko) 2023-03-21

Family

ID=52737037

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177025613A Active KR102513020B1 (ko) 2015-03-11 2016-03-10 암 바이오마커로서 pd-ecgf

Country Status (11)

Country Link
US (2) US11802874B2 (enExample)
EP (2) EP3067698A1 (enExample)
JP (3) JP2018512585A (enExample)
KR (1) KR102513020B1 (enExample)
CN (1) CN107667292B (enExample)
AU (1) AU2016231086B8 (enExample)
ES (1) ES2896056T3 (enExample)
HK (1) HK1250582A1 (enExample)
MX (1) MX384046B (enExample)
PL (1) PL3268744T3 (enExample)
WO (1) WO2016142471A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510835A (ja) * 2018-01-15 2021-04-30 フンダシオン インスティテュート デ インベスティガシオン サニタリア デ サンティアゴ デ コンポステーラ （フィディス） Ｔａｓ１ｒ３タンパク質を発現する腫瘍に関する治療目的、診断目的及び／又は予後診断目的のマーカーとしてのｔａｓ１ｒ３タンパク質の使用
US12624695B2 (en) 2024-09-19 2026-05-12 Mahle International Gmbh Oil separator for compressor and compressor with oil separator

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3268147B2 (ja) 1994-12-28 2002-03-25 大鵬薬品工業株式会社 モノクローナル抗体
US20050175980A1 (en) 2002-04-09 2005-08-11 Government Of The United States Of America, Repres By The Secretary, Dept. Of Health And Human Serv. Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
CN1882698B (zh) 2003-08-20 2011-05-25 肿瘤疗法科学股份有限公司 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
ES2279266T3 (es) * 2003-08-28 2007-08-16 F. Hoffmann-La Roche Ag Correlacion del cociente de los niveles de expresion del mrna de la timidina fosforilasa y la dihidropirimidina dehidrogenasa en el cancer colorrectal con supervivencia libre de enfermedad en pacientes tratados con 5-fu.
WO2007115376A1 (en) 2006-04-11 2007-10-18 The University Of Western Australia Anti-angiogenic agents and methods of their use
US8642349B1 (en) * 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
CA2751888C (en) * 2009-02-11 2022-06-14 Caris Mpi, Inc. Molecular profiling of tumors
US20120282631A1 (en) * 2009-03-20 2012-11-08 The Hong Kong Polytechnic University Method for diagnosis non-small-cell-lung-carcinoma (nsclc) and classification of its subtypes with different combinations of 6 protein biomarkers
US20100317029A1 (en) * 2009-06-15 2010-12-16 Lih-Chyang Chen Nasopharyngeal cancer malingancy biomarker and method thereof
US8110675B2 (en) 2009-06-15 2012-02-07 Chang Gung University TP expression-inhibiting compound and siRNA sequence thereof
CN101993919A (zh) * 2009-08-10 2011-03-30 芮屈生物技术（上海）有限公司 一种pd-ecgf基因的原位杂交检测试剂盒及其检测方法和应用
US9128101B2 (en) * 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
WO2012129448A1 (en) 2011-03-23 2012-09-27 The Regents Of The University Of California Methods and compositions for improving antiangiogenic therapy with anti-integrins
AU2013207778B2 (en) * 2012-01-13 2017-10-12 Genentech, Inc. Biological markers for identifying patients for treatment with VEGF antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Brostjan Christine et al, Cancer: Interdisciplinary International Journal of the American Cancer Society (2003), vol 98, no 10, pp 2291-2301.
Metzger Ralf et al, Clinical Cancer Research (1998), vol 4, no 10, pp 2371-2376.
Mizutani Yoichi et al, Cancer Society (2003), vol 98, no 4, pp 730-736.
Ruckaberle E et al, European Journal of Cancer (2010), vol 46, no 3, pp 549-557.
Takayama Tatsuya et al, Japanese Journal of Clinical Oncology (2006), vol 36, no 9, pp 564-569.
Tokunaga Yukihiko et al, Surgery (2002), vol 131, no 5, pp541-547.
Tsuji T et al, European Journal of Surgical Oncology (2004), vol 30, no 3, pp 296-302.

Also Published As

Publication number Publication date
AU2016231086B2 (en) 2021-08-12
US20180052164A1 (en) 2018-02-22
MX2017011467A (es) 2018-01-23
US12298307B2 (en) 2025-05-13
JP2018512585A (ja) 2018-05-17
PL3268744T3 (pl) 2021-12-27
HK1250582A1 (zh) 2019-01-04
EP3268744A1 (en) 2018-01-17
JP7453284B2 (ja) 2024-03-19
CN107667292B (zh) 2020-06-19
EP3268744B1 (en) 2021-08-11
EP3067698A1 (en) 2016-09-14
CN107667292A (zh) 2018-02-06
JP2022153482A (ja) 2022-10-12
WO2016142471A1 (en) 2016-09-15
US20240069029A1 (en) 2024-02-29
AU2016231086A1 (en) 2017-09-28
JP2020201278A (ja) 2020-12-17
AU2016231086B8 (en) 2022-02-03
US11802874B2 (en) 2023-10-31
CA2978653A1 (en) 2016-09-15
MX384046B (es) 2025-03-14
KR20170123638A (ko) 2017-11-08
ES2896056T3 (es) 2022-02-23
AU2016231086A8 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
JP5750152B2 (ja) 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット
JP5934093B2 (ja) 子宮内膜がんのマーカー
US12298307B2 (en) PD-ECGF as biomarker of cancer
CN103429757A (zh) 癌症诊断和治疗
EP2270510A1 (en) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
Kim et al. Prognostic significance of high expression of ER-beta in surgically treated ER-positive breast cancer following endocrine therapy
JP2003504073A (ja) Ｂａｇ発現のレベルを測定することによる、癌患者の予後を決定するための方法
CA2978653C (en) Pd-ecgf as biomarker of cancer
IL307530A (en) Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
US20230059578A1 (en) Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
EP2957913B1 (en) Methods and products for prognosing the clinical evolution, or predicting the recurrence risk, of a papillary lesion of the breast
EP3052938B1 (en) Methods and products for the diagnosis and prognosis of ovarian tumor malignancy
CN107850599A (zh) Wbp2与her2作为共预后因子对患者分层以进行治疗
EP4320443A1 (en) Protein markers for the prognosis of breast cancer progression
HK1243168A1 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
HK1163182A (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4